Clinical Trials Sponsored by Orexigen Therapeutics, Inc

Total 2996 results

T3D Therapeutics, Inc.

Completed

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Melinta Therapeutics, Inc.

Terminated

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

Gonorrhea

United States
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
Gila Therapeutics, Inc.

Completed

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

Feeding and Eating Disorders

United States
Axsome Therapeutics, Inc.

Unknown

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 (CREATE-1)

Reflex Sympathetic Dystrophy | Complex Regional Pain Syndrome

United States, United Kingdom, Australia, Canada
Obalon Therapeutics, Inc.

Completed

Obalon Balloon System Pivotal IDE (SMART) Trial (SMART)

Obesity

United States
InteKrin Therapeutics, Inc.

Completed

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

Multiple Sclerosis, Relapsing Remitting
CymaBay Therapeutics, Inc.

Completed

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Gout

United States, Canada, Georgia
CymaBay Therapeutics, Inc.

Terminated

Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis (PBC)

Germany, United States, Canada, United Kingdom, Poland
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Dravet Syndrome
Realm Therapeutics, Inc.

Unknown

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Avalo Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Major Depressive Disorder

United States
Chrono Therapeutics, Inc.

Completed

Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects

Smoking Cessation

United States
Tobira Therapeutics, Inc.

Completed

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Healthy

United States
Melinta Therapeutics, Inc.

Completed

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue Infections

United States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
Aciex Therapeutics, Inc.

Completed

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Allergic Conjunctivitis

United States
Millendo Therapeutics, Inc.

Completed

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Adrenocortical Carcinoma | Adrenal Cancer | ACC

United States, Germany
Anika Therapeutics, Inc.

Completed

Safety Study of Cosmetic Tissue Augmentation in People of Color

Wrinkles

United States
Aciex Therapeutics, Inc.

Completed

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Healthy

United States
Aciex Therapeutics, Inc.

Completed

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Atopic Disease (Including Allergic Conjunctivitis)

United States
INSYS Therapeutics Inc

Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Post-operative Pain

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Healthy Volunteers

Canada
INSYS Therapeutics Inc

Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Acute Pain

United States
Onconova Therapeutics, Inc.

Completed

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative Disease

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET)

Myelodysplastic Syndrome | MDS | Trisomy 8

United States
Onconova Therapeutics, Inc.

Completed

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Elcelyx Therapeutics, Inc.

Completed

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

Type 2 Diabetes Mellitus
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Intrepid Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Androgenetic Alopecia

United States
Melinta Therapeutics, Inc.

Completed

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia

United States, Canada
Vyne Therapeutics Inc.

Completed

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)

Rosacea | Papulopustular Rosacea

Germany
BlackThorn Therapeutics, Inc.

Completed

A Study of LY2940094 in Major Depressive Disorder

Major Depressive Disorder

Canada
Nivalis Therapeutics, Inc.

Completed

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) ((SNO-9))

Cystic Fibrosis

United States
Cara Therapeutics, Inc.

Completed

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis

United States
Alcresta Therapeutics, Inc.

Completed

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Exocrine Pancreatic Insufficiency

United States
Nivalis Therapeutics, Inc.

Unknown

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor (SNO-7)

Cystic Fibrosis

United States
Nivalis Therapeutics, Inc.

Completed

PK Study of N91115 in Cystic Fibrosis Patients (SNO3)

Cystic Fibrosis

United States
Mast Therapeutics, Inc.

Completed

Evaluation of Repeat Administration of Purified Poloxamer 188 (EPIC-E)

Sickle Cell Disease

United States
Carbylan Therapeutics, Inc.

Completed

Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis

Osteoarthritis of the Knee

Canada, Australia, Netherlands Antilles
Cara Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pruritus | Uremic Pruritus

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Lisata Therapeutics, Inc.

Completed

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)

ST Segment Elevation Myocardial Infarction

United States
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine

3

Subscribe